During the 16-week placebo-controlled study period , 31.4 % and 30.6 % of patients had adverse events ( AEs ) in groups 1 and 2 , respectively ; similar AE reporting rates were observed through week 24 ( 34.3 % and 32.0 % ) and among the golimumab-treated patients through week 56 ( 41.2 % ) .